Role of FSHR Polymorphism p.N680S in the Therapy With FSH in Patients Who Underwent Varicocele Surgery
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Two common SNPs are located in linkage disequilibrium in exon 10 of FSHR. The 2039 A>G
variant is regularly analyzed to characterize the exon 10 haplotype. In the last years, it
has been showed an influence of FSHR 2039 A>G on FSH levels, testicular volume, sperm
concentration and the total sperm count. A recent Cochrane review showed a beneficial effect
on live birth and pregnancy of gonadotrophin treatment for men with idiopathic male factor
subfertility. Which FSHR polymorphism can benefit from FSH treatment is clinically very
important, in particular for what regards nonidiopathic patients. In many andrological units,
patients underwent adiuvant therapy with purified or recombinant FSH after varicocelectomy.
FSH treatment in patients after varicocelectomy could improve spermatogenesis, but there
aren't multicentric trials that confirm its validity. Usually, in our hospital only patients
with a morphologic aspect of hypospermatogenesis underwent therapy with purified or
recombinant FSH, because this therapy is not much useful in patient with Partial
Sertoli-cell-only syndrome or maturation arrest. The purpose of our study is to correlate
"non responder" patients who underwent FSH adiuvant therapy after varicocele surgery with a
p.N680S FSHR polymorphism. Moreover the investigators suppose that "non responder" patients
can beneficiate from a high-dose therapy with FSH. This is a prospective intervention study
in which are recruited males with OligoAstenoTeratozoospermic (OAT) and varicocele. The
partecipants will undergo subinguinal microsurgical varicocelectomy (Marmar technique) and
needle aspiration testicular cytology (Foresta technique).